Q1 2026

Filed Apr 29, 2026 · 10-Q · 29 days after period end · 0000875045-26-000045

Q1 2026 · 10-Q

Revenue

$2.48B

+1.9% vs Q1 2025

Net Income

$319.50M

+32.8% vs Q1 2025

EPS Diluted

$2.15

+31.1% vs Q1 2025

Operating Cash Flow$645,500,000+148.9%

Free Cash Flow

Same quarter

Metric	Q1 2026	Q1 2025	Q1 2024	Q1 2023
Revenue	$2.48B	$2.43B	$2.29B	$2.46B
Net Income	$319.50M	$240.50M	$393.40M	$387.90M
EPS Diluted	$2.15	$1.64	$2.70	$2.67

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR